Exploring Theranostic Potentials of Radioiodinated Hypericin in Rodent Necrosis Models

Theranostics

Volumn 2, Issue 10, 2012, Pages 1010-1019

  Li, Junjie ^a,b   Cona, Marlein Miranda ^a,b   Chen, Feng ^a,b   Feng, Yuanbo ^a,b   Zhou, Lin ^a   Yu, Jie ^a   Nuyts, Johan ^a   de Witte, Peter ^c   Zhang, Jian ^d   Himmelreich, Uwe ^b   Verbruggen, Alfons ^c   Ni, Yicheng ^a,b,d  

^a DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^b KU Leuven   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Laboratory of Translational Medicine   (China)

Author keywords

Malignancies; Necrosis avidity; Radioiodinated hypericin; Theranostic

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; EVANS BLUE; HYPERICIN; HYPERICIN I 123; HYPERICIN I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; INFARCTION; LIVER NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLANAR GAMMA SCINTIGRAPHY; RADIOACTIVITY; RAT; REPERFUSED LIVER INFARCTION; RHABDOMYOSARCOMA; SCINTIGRAPHY;

EID: 84870478186     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.4924     Document Type: Article

References (30)

1. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 2002;31:214-23.
2. Dasari M, Lee S, Sy J, et al. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Org Lett. 2010;12:3300-3.
3. Walker NI, Harmon BV, Gobe GC, et al. Patterns of cell death. Methods Achiev Exp Pathol. 1988;13:18-54.
4. Ni Y, Bormans G, Chen F, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol 2005;40:526-35.
5. Flotats A, Carrio I. Non-invasive in vivo imaging of myocardial apopto-sis and necrosis. Eur J Nucl Med Mol Imaging 2003;30:615-30.
6. Epstein A, Chen F, Taylor C. A novel method for the detection of necrotic lesions in human cancers. Cancer Res 1988; 48:5842-8.
7. Chen F, Taylor C, Epstein A. Tumor necrosis treatment of Me-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578-85.
8. Ni Y, Huyghe D, Verbeke K, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging 2006;33: 595-601.
9. Fonge H, Vunckx K, Wang H, et al. Noninvasive detection and quanti-fication of acute myocardial infarction in rabbits using mono- [123I]iodohypericin microSPECT. Eur Heart J. 2008;29:260-269.
10. Ni Y, Bormans G, Marchal G, et al. Necrosis avid tracer agent. European patent EP1651201B1; January 2, 2008; Priority July 25, 2003.
11. Van de Putte M, Wang H, Chen F, et al. Hypericin as a marker for de-termination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep. 2008;19:927-932.
12. Van de Putte M, Ni Y, De Witte PA. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep. 2008;19:921-6.
13. Song, S., Xiong, C., Zhou, M., et al. Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med. 2011;52:792-9.
14. Cona MM, Wang H, Li J, et al. Continuing pursuit for ideal systemic anticancer radiotherapeutics. Invest New Drugs. 2011; DOI: 10.1007/s10637-011-9758-6.
15. Li J, Sun Z, Zhang J, et al. A dual-targeting anticancer approach: soil and seed principle. Radiology. 2011;260:799-807.
16. Li J, Chen F, Cona MM, et al. A Review on Various Targeted Anticancer Therapies. Target Oncol. Mar 2012;7:69-85. DOI: 10.1007/s11523-012-0212-2.
17. Van de Putte M, Marysael T, Fonge H, et al. Radiolabeled iodohypericin as tumor necrosis avid tracer: diagnostic and therapeutic potential. Int. J. Cancer: 2012; 131(2):E129-37. DOI: 10.1002/ijc.26492.
18. Wu X, Wang H, Chen F, et al. Rat model of reperfused partial liver infarction: characterization with multiparametric magnetic resonance imaging, microangiography, and histomorphology. Acta Radiol. 2009;50:276-87.
19. Chen F, Sun X, De Keyzer F, et al. Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histo-pathologic analysis. Radiology 2006; 239:554-62.
20. Wang H, Sun X, Chen F, et al. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with mi-croangiography and histology. Invest Radiol. 2009;44:44-53.
21. Fonge H, Van de Putte M, Huyghe D, et al. Evaluation of tumor affinity of mono-[(123)I]iodohypericin and mono-[(123)I]iodoprotohypericin in a mouse model with a RIF-1 tumor. Contrast Media Mol Imaging. 2007;2:113-9.
22. Ni Y, Wang H, Chen F, et al. Tumor models and specific contrast agents for small animal imaging in oncology. Methods. 2009;48:125-38.
23. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans blue dye as an in vivo marker of myofibre damage: optimising parameters for de-tecting initial myofibre membrane permeability, J. Anat. 2002; 200: 69-79.
24. Bormans G, Huyghe D, Christiaen A, et al. Preparation, analysis and biodistribution in mice of iodine-123 labelled derivatives of hypericin. J Labelled Comp Rad. 2004;47:191-198.
25. Van De Putte M, Roskams T, Bormans G, et al. The impact of aggregation on the biodistribution of hypericin. Int J Oncol. 2006;28:655-60.
26. Tozer GM, Kanthou C, et al. Tumour vascular disrupting agents: com-bating treatment resistance. Br J Radiol. 2008;81:S12-S2.
27. Kelvin S.H Loke, Ajit K Padhy, David C.E Ng, et al. Dosimetric Consid-erations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review. World J Nucl Med. 2011;10:122-38.
28. Welford AF, Biziato D, Coffelt SB, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent com-bretastatin A4 phosphate in mice. J Clin Invest. 2011;121:1969-1973.
29. Hofer KG. Heat potentiation of radiation damage versus radiation po-tentiation of heat damage. Radiat Res. 1987;110:450-7.
30. Li J, Miranda CM, Feng Y, Chen F, Zhang G, Fu X, Himmelreich U, Oyen R, Verbruggen A, Ni Y. A Single-dose Toxicity Study of Non-radioactive Iodinated Hypericin for a Targeted Anticancer Therapy in Mice. Acta Pharmacologica Sinica. 2012; Doi: 10.1038/aps.2012.111.